Compound ID | 2431
Synonym(s): Rifamycin-nitroimidazole conjugate | TNP-2198
Class: Small molecule antibacterial agent
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | RNA synthesis inhibitor. RNA polymerase inhibitor |
| Target Pathogen: | Active against Helicobacter pylori and Clostridioides difficile |
| Description: | Synthetic compound |
| Institute where first reported: | TenNor Therapeutics Ltd, 218 Xinghu Street, Suzhou Industrial Park, Suzhou 215123, China |
| Year first mentioned: | 2022 |
| Highest development stage: | Phase 3 (NCT05857163) |
| Development status: | Active |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/136014272 |
| Guide to Pharmacology: | rifasutenizol |
| Citation: | https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c02045 |
| Patent: | WO2020078154 |